Načítá se...
Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
In preclinical in vivo models of cancer, the induction of immunogenic cell death (ICD) sensitizes to subsequent immunotherapy. Several clinical trials now confirm that pretreatment with ICD-inducing anthracyclines sensitizes to immune checkpoint blockade targeting PD-1 and PD-L1 interaction. These f...
Uloženo v:
| Vydáno v: | Oncoimmunology |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6791413/ https://ncbi.nlm.nih.gov/pubmed/31646079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1637188 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|